Alnylam Pharmaceuticals Inc "RNAi Roundtable" Webcast Series: Patisiran & Vutrisiran, in Development for the Treatment of ATTR Amyloidosis Transcript
Good morning, everyone. Thank you for joining us for this RNAi roundtable. Today, we'll be discussing our growing ATTR amyloidosis franchise, which includes patisiran and Vutrisiran as well as our newest addition to the franchise, our preclinical program, ALN-TTRsc04. I'm Josh Brodsky, Senior Director of Investor Relations and Corporate Communications at Alnylam. With me today are Rena Denoncourt, Vice President, ATTR franchise lead; John Vest, Vice President of Clinical Research and Clinical Lead for the ATTR amyloidosis franchise; Rebecca Shilling, Director of Clinical Research and Clinical Lead for the HELIOS-A study; Patrick Jay, Director of Clinical Research and Clinical Lead for the Post OLT study; and Dr. Mat Maurer, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Medical Center and the key opinion leader in the treatment of ATTR amyloidosis.
Today's RNAi roundtable is the second in a series of roundtable webinars that we'll be hosting over the next few months to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
